Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Shabir Madhi and Anthonet Koen.
Shabir Madhi
Connection Strength
5,451
Anthonet Koen
  1. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005). Vaccine. 2023 05 26; 41(23):3486-3492.
    View in: PubMed
    Score: 0,867
  2. Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
    View in: PubMed
    Score: 0,245
  3. Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
    View in: PubMed
    Score: 0,240
  4. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial. Lancet Child Adolesc Health. 2023 05; 7(5):326-335.
    View in: PubMed
    Score: 0,215
  5. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa. AIDS. 2023 01 01; 37(1):105-112.
    View in: PubMed
    Score: 0,209
  6. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
    View in: PubMed
    Score: 0,209
  7. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
    View in: PubMed
    Score: 0,193
  8. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
    View in: PubMed
    Score: 0,187
  9. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials. Expert Rev Vaccines. 2020 12; 19(12):1177-1189.
    View in: PubMed
    Score: 0,184
  10. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2021 06 03; 17(6):1770-1778.
    View in: PubMed
    Score: 0,184
  11. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
    View in: PubMed
    Score: 0,180
  12. Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. Vaccine. 2020 05 08; 38(22):3862-3868.
    View in: PubMed
    Score: 0,176
  13. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 2020 02 28; 38(10):2350-2360.
    View in: PubMed
    Score: 0,173
  14. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children. J Infect Dis. 2019 09 26; 220(9):1529-1538.
    View in: PubMed
    Score: 0,169
  15. Neutrophil Counts in Healthy South African Infants: Implications for Enrollment and Adverse Event Grading in Clinical Trials in an African Setting. J Pediatr X. 2019; 1:100005.
    View in: PubMed
    Score: 0,161
  16. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
    View in: PubMed
    Score: 0,149
  17. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial. Expert Rev Vaccines. 2017 06; 16(6):641-656.
    View in: PubMed
    Score: 0,144
  18. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine (Baltimore). 2017 Jan; 96(2):e5881.
    View in: PubMed
    Score: 0,140
  19. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016 08; 16(8):923-34.
    View in: PubMed
    Score: 0,134
  20. Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants. PLoS One. 2015; 10(4):e0123014.
    View in: PubMed
    Score: 0,124
  21. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ. 2014 Apr 01; 92(4):238-45.
    View in: PubMed
    Score: 0,114
  22. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One. 2013; 8(8):e72794.
    View in: PubMed
    Score: 0,111
  23. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
    View in: PubMed
    Score: 0,110
  24. Acquisition of Streptococcus pneumoniae in pneumococcal conjugate vaccine-naïve South African children and their mothers. Pediatr Infect Dis J. 2013 May; 32(5):e192-205.
    View in: PubMed
    Score: 0,109
  25. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,092
  26. Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial. J Infect. 2024 Dec; 89(6):106285.
    View in: PubMed
    Score: 0,060
  27. Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
    View in: PubMed
    Score: 0,058
  28. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
    View in: PubMed
    Score: 0,055
  29. Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):273-281.
    View in: PubMed
    Score: 0,055
  30. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses. 2023 02 06; 15(2).
    View in: PubMed
    Score: 0,053
  31. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis. 2022 Oct; 22(10):1472-1483.
    View in: PubMed
    Score: 0,051
  32. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine. 2021 09 15; 39(39):5513-5523.
    View in: PubMed
    Score: 0,048
  33. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
    View in: PubMed
    Score: 0,047
  34. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
    View in: PubMed
    Score: 0,046
  35. HLA antibody repertoire in infants suggests selectivity in transplacental crossing. Am J Reprod Immunol. 2020 08; 84(2):e13264.
    View in: PubMed
    Score: 0,044
  36. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020 07; 20(7):851-863.
    View in: PubMed
    Score: 0,044
  37. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017 08; 17(8):843-853.
    View in: PubMed
    Score: 0,036
  38. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016 May; 16(5):546-555.
    View in: PubMed
    Score: 0,033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.